Semaglutide New Drug Combo Well-Tolerated, Leads to Weight Loss
Combining an investigational agent, cagrilintide (Novo Nordisk), with semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, results in extra weight reduction than semaglutide by myself in humans with a frame mass index (BMI) over 27 kg/m2, and the aggregate turned into well-tolerated, indicates section 1 take a look at.
The studies turned into supplied at the web ECO 2021 assembly with the aid of using Lone Enebo, Ph.D., from Novo Nordisk, Denmark, and concurrently posted in The Lancet.
“Treatment with cagrilintide in any respect examined doses in aggregate with semaglutide 2. four mg turned into normally well-tolerated with a suitable protection profile,” says Enebo and coauthors, including that no obvious distinction turned into visible withinside the wide variety of unfavorable activities throughout remedy groups.
“The records guide as soon as-weekly dosing. The aggregate of cagrilintide is 1.2, 2. four, or four. five mg plus semaglutide 2. four mg caused extra weight reduction as compared with semaglutide 2. four mg only.”
The as soon as-weekly dosing routine related to a clinically significant weight reduction of as much as 17.1% of frame weight without a way of life interventions.
“These records guide the similarly scientific improvement of cagrilintide and semaglutide 2. four mg as a capability novel and powerful aggregate remedy for weight control,” they upload.
In an accompanying commentary, Sara Becerril, Ph.D. candidate, and Gema Frühbeck, MD, from the University of Navarra, Pamplona, Spain, said: “Approved pharmacological remedy options [for overweight and obesity] are scarce and do now no longer satisfactorily bridge the distance in efficacy among way of life behavioral modifications and bariatric surgery to acquire sustained long-time period results.”
But they emphasize: “Because the take a look at turned into designed for protection, the weight reduction results want to be analyzed with caution. No way of life intervention turned into prescribed to provide weight reduction…Moreover, the protocol turned into amended to encompass the best which could have been records-driven.”
Study Conducted withinside the US.
Semaglutide is presently accepted at a dose of 1. zero mg injected subcutaneously as soon as weekly for the remedy of kind 2 diabetes and as an oral agent for the equal indication. It is being evolved for persistent weight control at a dose of 2. four mg injected subcutaneously as soon as weekly. New drug packages are below evaluated for the remedy of obesity using the American Food and Drug Administration, the European Medicines Agency, and different fitness agencies, with a choice at the US approval anticipated soon.
The STEP trials that have been posted in diverse journals during the last year have mounted the efficacy and protection of semaglutide 2. four mg to deal with humans with obesity.
For the cutting-edge take a look at, carried out inside the United States, ninety-six individuals, of whom ninety-five have been uncovered to remedy, elderly 18-fifty five years with a BMI of 27.zero-39.nine kg/m² who have been in any other case wholesome have been randomized to cagrilintide (zero.16-2.four mg, n = 12 in every group; four.five mg group, n = 11) or placebo (n = 24) in aggregate with semaglutide 2.four mg. Mean age turned into 40.6 years, 59% of contributors have been men, and 54% have been Black or African American.
The number one endpoint turned into a wide variety of remedy-emergent unfavorable activities from baseline to follow-up (cease of week 25).
No Clear Differences in Adverse Events Between Groups
Most unfavorable activities mentioned have been moderate or slight in severity, and there have been no obvious variations among remedy groups: activities have been mentioned in 69/seventy contributors taking zero.16-four: five mg cagrilintide and 23/24 on placebo.
Contributors mentioned two intense unfavorable activities: one with cagrilintide 1.2 mg in aggregate with semaglutide 2. four mg (viral meningitis), and one withinside the pooled placebo in aggregate with semaglutide 2. four mg group (serum creatinine increase). Both the activities have been deemed not likely to be associated with taking a look at remedy.
The maximum, not unusual place unfavorable activities mentioned have been gastrointestinal problems in 77% of contributors, maximum regular nausea in 56%, vomiting in 24%, and dyspepsia in 28%. On placebo, 79% of contributors skilled gastrointestinal activities.
At week 20, suggest percent frame weight discounts from baseline have been extra with cagrilintide 1.2 mg (15.7%) and 2. four mg (17.1%) than for pooled placebo (nine.8%).
Cagrilintide four. Five mg caused a median weight loss of 15.four% compared with 8.zero% for placebo (each plus semaglutide).
“Mean frame weight discounts on this trial have been additionally extra than the ones determined in 26 weeks with cagrilintide by me (as much as 7.8% discount in frame weight relative to placebo with four. five-mg dose),” upload the authors, regarding preceding studies.
Phase three Trial Program With Cagrilintide Is Planned.
Enebo and coauthors explain that cagrilintide is the concept to affect meal alternatives by focusing on each homeostatic and hedonic area of the mind to result in satiety.
“Although each semaglutide and cagrilintide [both] result in satiety, they function in exclusive areas of the mind, which would possibly bring about an additive impact on urge for food regulation. Moreover, the capability for cagrilintide to affect meals alternatives would possibly make contributions to the change of ingesting behaviors, similarly enhancing remedy efficacy.”
“Our records guide the similarly scientific improvement of this drug aggregate for weight control. A section three trial software is now being deliberate to check cagrilintide in aggregate with semaglutide for weight control,” they conclude.
ECO 2021. Session AD12.04. Presented May 13, 2021.
Lancet. Published online April 22, 2021. Abstract
About Post Author
